Therapy Areas: Diabetes
LyGenesis granted funding for research project to induce immune tolerance to pancreatic islet transplantation
26 June 2026 - LyGenesis, Inc., a US-based, clinical-stage biotechnology company developing cell therapies for organ regeneration, announced on Thursday that it has received a research award from Brea...
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
25 June 2026 - Cirius Therapeutics Inc, a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, announced on Wednesday that e...
Novo Nordisk Foundation funds European initiative to accelerate drug discovery for cardiometabolic diseases
22 June 2026 - The Novo Nordisk Foundation, a philanthropic enterprise foundation created by Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO), announced on Friday that it is fund...
Bayer completes acquisition of Perfuse Therapeutics to strengthen ophthalmology pipeline
17 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) confirmed on Wednesday that it has completed the acquisition of Perfuse Therapeutics Inc.Through this acq...
Sciwind Biosciences reports positive study data on ecnoglutide versus semaglutide
8 June 2026 - Hangzhou Sciwind Biosciences Co Ltd, a China-based, commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, announce...
Bayer reports positive Phase III FIND-CKD results for Kerendia in non-diabetic chronic kidney disease
5 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) on Friday reported full results from the Phase III FIND-CKD trial evaluating Kerendia (finerenone) in adul...